Fintel reports that on June 3, 2025, Oppenheimer initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Outperform ...

Discover Axsome Therapeutics (NASDAQ:AXSM), a pioneering biopharmaceutical company dedicated to creating innovative ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Purohit’s continued optimism is primarily driven by the strong commercial performance of Auvelity, the company’s treatment ...

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

Many investors love the "big mo." That's short for "big momentum." Stocks that are on a roll often keep the good times going.

Axsome Therapeutics, Inc. has announced a settlement with Hetero Labs Ltd. regarding patent litigation over its product SUNOSI® (solriamfetol). The litigation arose from Hetero's application to ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...